US-based DEKA Medical has recently received clearance from the US Food and Drug Administration (FDA) for its Synchro REPLA: Y laser, designed for a variety of aesthetic treatments.
The FDA clearance is for its combined laser and light-based hair reduction and skin treatment for benign pigmented lesions, wrinkles and photocoagulation of vascular lesions.
The new Synchro system uses three different light sources, a 755nm Alexandrite laser, a 1064nm Nd:YAG laser and an intense pulsed light, that can remove hair and perform skin treatments such as rejuvenation and treatment of vascular lesions.
Lasers feature spot sizes from 2.5mm to 20mm, while the intense pulsed light includes five filters, from 500nm to 650nm lower cut-off wavelength, allowing a broad range of effective and safe treatments.
The powerful, fast, complete Synchro REPLA: Y system combines hair removal on all Fitzpatrick skin types, including tanned skin, vascular and benign pigmented lesions treatments, as well as skin rejuvenation, in a single platform.
American Society for Laser Medicine and Surgery fellow director of Kassir Dermatology, Dallas, Texas, Dr Martin Kassir said: "The energies, varying pulse widths and pulse shape and the large (20 mm) spot sizes represent an advancement in technology, that results in faster, better tolerated and more reliable treatments.
"I am very excited to be the first dermatologist in North America to use the Synchro REPLA:Y and to offer its benefits to my patients."
The Synchro REPLA: Y anticipates the future, including for the first time in one system one powerful (125W) and fast (3Hz, while the industry standard is still 2Hz) Alexandrite laser, together with one powerful (150W) and fast Nd:YAG laser with unrivaled characteristics.